Related Experiment Video
Updated: Apr 4, 2026

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
Orally bioavailable Syk inhibitors with activity in a rat PK/PD model
Gebhard Thoma1, Siem Veenstra1, Ross Strang1
1Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.
Abstract:
Design and optimization of benzo- and pyrido-thiazoles/isothiazoles are reported leading to the discovery of the potent, orally bioavailable Syk inhibitor 5, which was found to be active in a rat PK/PD model. Compound 5 showed acceptable overall kinase selectivity. However, in addition to Syk it also inhibited Aurora kinase in enzymatic and cellular settings leading to findings in the micronucleus assay. As a consequence, compound 5 was not further pursued.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
Measurement of Bioavailability: Pharmacodynamic Methods
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions